csirt@kutim:~/threat-intel/cve/CVE-2024-28199

Katalog CVE

CVSS 6.1 · Medium EPSS 0,60%

Kerentanan Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') pada phlex. Skor CVSS 3.1 6.1 (Medium) menurut NVD.

Deskripsi (NVD)

phlex is an open source framework for building object-oriented views in Ruby. There is a potential cross-site scripting (XSS) vulnerability that can be exploited via maliciously crafted user data. This was due to improper case-sensitivity in the code that was meant to prevent these attacks. If you render an `<a>` tag with an `href` attribute set to a user-provided link, that link could potentially execute JavaScript when clicked by another user. If you splat user-provided attributes when rendering any HTML tag, malicious event attributes could be included in the output, executing JavaScript when the events are triggered by another user. Patches are available on RubyGems for all 1.x minor versions. Users are advised to upgrade. Users unable to upgrade should consider configuring a content security policy that does not allow `unsafe-inline`.

Rincian

Terbit di NVD
11 Maret 2024
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
6.1 (Medium), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-79: Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')
EPSS (30 hari)
0,60% peluang dieksploitasi; lebih tinggi dari 47,4% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
phlex phlex Semua versi sebelum 1.0.1
phlex phlex Versi 1.2.0 hingga sebelum 1.2.2
phlex phlex Versi 1.3.0 hingga sebelum 1.3.3
phlex phlex Versi 1.1.0
phlex phlex Versi 1.4.0
phlex phlex Versi 1.7.0
phlex phlex Versi 1.9.0

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.